Acetate restores hypothalamic-adipose kisspeptin status in a rat model of PCOS by suppression of NLRP3 immunoreactivity

Olaniyi, Kehinde S.; Areloegbe, Stephanie E.; Oyeleke, Mosunmola B.

doi:10.1007/s12020-022-03191-9

Cited by 13 publications

(11 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given the scarcity of human studies, we decided to include both human and animal articles. Nine studies were deemed eligible and were included in the systematic review including three human studies [ 60 , 61 , 62 ] and six animal studies [ 63 , 64 , 65 , 66 , 67 , 68 ]. Two of the human studies measured NLRP3 in PBMC and one in luteinised granulosa cells ( Table 3 ).…”

Section: Resultsmentioning

confidence: 99%

The Role of NLRP3 Inflammasome in Obesity and PCOS—A Systematic Review and Meta-Analysis

Alenezi

Khan

Snell

et al. 2023

IJMS

View full text Add to dashboard Cite

Inflammasomes have recently been implicated in the pathogenesis of several chronic inflammatory disorders, such as diabetes and obesity. The aim of this meta-analysis was to investigate the possible role of the NLRP3 inflammasome in obesity and polycystic ovarian syndrome (PCOS). A comprehensive search of electronic databases was conducted to identify studies investigating NLRP3 its related components (Caspase 1, ASC and IL-1β) in adipose tissue and/or blood from obese individuals compared to non-obese controls. Another search was conducted for studies investigating NLRP3 in PCOS women and animal models. The ssearched databases included Medline, EMBASE, Cochrane Library, PubMed, Clinicaltrials.gov, the EU Clinical Trials Register and the WHO International Clinical Trials Register. The quality and risk of bias for the included articles were assessed using the modified Newcastle–Ottawa scale. Data were extracted and pooled using RevMan software for the calculation of the standardized mean difference (SMD) and 95% confidence interval (CI). Twelve eligible studies were included in the obesity systematic review and nine in the PCOS review. Of the obesity studies, nine (n = 270) were included in the meta-analysis, which showed a significantly higher adipose tissue NLRP3 gene expression in obese (n = 186) versus non-obese (n = 84) participants (SMD 1.07; 95% CI, 0.27, 1.87). Pooled analysis of adipose tissue IL-1β data from four studies showed significantly higher IL-1β gene expression levels in adipose tissue from 88 obese participants versus 39 non-obese controls (SMD 0.56; 95% CI, 0.13, 0.99). Meta-analysis of adipose tissue ASC data from four studies showed a significantly higher level in obese (n = 109) versus non-obese (n = 42) individuals (SMD 0.91, 95% CI, 0.30, 1.52). Of the nine PCOS articles, three were human (n = 185) and six were animal studies utilizing PCOS rat/mouse models. All studies apart from one article consistently showed upregulated NLRP3 and its components in PCOS women and animal models. In conclusion, obesity and PCOS seem to be associated with upregulated expression of NLRP3 inflammasome components. Further research is required to validate these findings and to elucidate the role of NLRP3 in obesity and PCOS.

show abstract

Section: Resultsmentioning

confidence: 99%

The Role of NLRP3 Inflammasome in Obesity and PCOS—A Systematic Review and Meta-Analysis

Alenezi

Khan

Snell

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Additionally, kisspeptin is a peptide in the hypothalamus to modulate gonadotropin secretion. Acetate reversed downregulated kisspeptin in PCOS in a rat model by suppressing NLRP3 immunoreactivity, with subsequent improvement of hypothalamic inflammation and endocrine profile 75 . Olaniyi et al suggested that acetate inhibited pyruvate dehydrogenase kinase 4 and histone deacetylase in letrozole‐induced rats.…”

Section: Gut Microbiota Is a Significant Target For Berberine Treatin...mentioning

confidence: 99%

“…Acetate reversed downregulated kisspeptin in PCOS in a rat model by suppressing NLRP3 immunoreactivity, with subsequent improvement of hypothalamic inflammation and endocrine profile. 75 Olaniyi et al…”

mentioning

confidence: 99%

Berberine interacts with gut microbiota and its potential therapy for polycystic ovary syndrome

Zhu,

2023

Clin Exp Pharma Physio

View full text Add to dashboard Cite

Berberine (BBR) is an isoquinoline alkaloid extracted from Chinese medicinal plants showing a tight correlation with gut microbiota. Polycystic ovary syndrome (PCOS) is a prevalent reproductive and endocrine disorder syndrome among women of childbearing age. Dysbiosis, the imbalance of intestinal microorganisms, is a potential factor that takes part in the pathogenesis of PCOS. Recent evidence indicates that berberine offers promise for treating PCOS. Here, we review the recent research on the interaction between berberine and intestinal microorganisms, including the changes in the structure of gut bacteria, the intestinal metabolites after BBR treatment, and the effect of gut microbiota on the bioavailability of BBR. We also discuss the therapeutic effect of BBR on PCOS in terms of gut microbiota and its potential mechanisms.

show abstract

“…(2020) [80] Prospective study − Patients with PCOS comorbid psychological distress (2022) [81] In vivo: (2022) [86] In [92] In vitro: (2017) [94] In vivo: (2022) [101] In vitro: rat model of PCOS. Moreover, QUR reduced the nuclear translocation of NF-κB in GCs.…”

Section: Guo Et Almentioning

confidence: 99%

“…The findings highlight the potential therapeutic benefits of acetate in managing PCOS‐related complications in female rats. [ 81 ] Diacerein (DIA), a symptomatic slow‐acting medication commonly used for osteoarthritis management, exhibits several pharmacological properties on synovial membrane and cartilage, including anti‐catabolic, anti‐inflammatory, and pro‐anabolic effects. [ 82 ] DIA blocks IL‐1β receptors and inhibits the IL‐1β transforming enzyme, which is crucial for the secretion of IL‐1β.…”

Section: Treatment Of Pcos Through the Regulation Of Nlrp3mentioning

confidence: 99%

Inhibition of NLRP3 inflammasome—A potential mechanistic therapeutic for treatment of polycystic ovary syndrome?

Chamanara,

Hozouri,

Irandoost

2023

J Biochem & Molecular Tox

View full text Add to dashboard Cite

This review article explores the relationship between the NOD‐like receptor protein 3 (NLRP3) inflammasome and the risk of developing polycystic ovary syndrome (PCOS). The NLRP3 inflammasome, a fundamental element of the innate immune system, plays a crucial role in the production of proinflammatory mediators and pyroptosis, a type inflammatory cell death. We conducted a thorough search on scientific databases to gather relevant information on this topic, utilizing relevant keywords. The reviewed studies indicated a correlation between PCOS and a higher incidence of granulosa cell (GC) death and the presence of ovarian tissue fibrosis. NLRP3 inflammasome stimulation and subsequent pyroptosis in GCs play a significant role in the pathophysiology of PCOS. Active NLRP3 inflammasome is involved in the production of inflammatory mediators like interleukin‐1β (IL‐1β) and IL‐18, contributing to the development of PCOS, particularly in overweight patients. Therefore, inhibiting NLRP3 activation and pyroptosis could potentially offer novel therapeutic strategies for PCOS. Some limited studies have explored the use of agents with antioxidant and anti‐inflammatory properties, as well as gene therapy approaches, to target the NLRP3 and pyroptosis signaling pathways. This study overview the understanding of the relationship between NLRP3 inflammasome activation, pyroptosis, and PCOS. It highlights the potential of targeting the NLRP3 inflammasome as an approach for treating PCOS. Nonetheless, further research and clinical trials are imperative to validate these results and explore the effectiveness of NLRP3 inflammasome inhibition in the management of PCOS.

show abstract

Acetate restores hypothalamic-adipose kisspeptin status in a rat model of PCOS by suppression of NLRP3 immunoreactivity

Cited by 13 publications

References 50 publications

The Role of NLRP3 Inflammasome in Obesity and PCOS—A Systematic Review and Meta-Analysis

The Role of NLRP3 Inflammasome in Obesity and PCOS—A Systematic Review and Meta-Analysis

Berberine interacts with gut microbiota and its potential therapy for polycystic ovary syndrome

Inhibition of NLRP3 inflammasome—A potential mechanistic therapeutic for treatment of polycystic ovary syndrome?

Contact Info

Product

Resources

About